Research Analysts’ Weekly Ratings Updates for Axsome Therapeutics (AXSM)

Several analysts have recently updated their ratings and price targets for Axsome Therapeutics (NASDAQ: AXSM):

• 7/20/2026 – Axsome Therapeutics is now covered by BMO Capital Markets. They set an “outperform” rating and a $310.00 price target on the stock.
• 7/20/2026 – Axsome Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/20/2026 – Axsome Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 7/17/2026 – Axsome Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $290.00 price target on the stock.
• 7/8/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $290.00 price target on the stock.
• 7/7/2026 – Axsome Therapeutics had its price target raised by Royal Bank Of Canada from $302.00 to $304.00. They now have an “outperform” rating on the stock.
• 6/17/2026 – Axsome Therapeutics had its price target raised by TD Cowen from $275.00 to $300.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Axsome Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 6/11/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $380.00 price target on the stock.
• 6/11/2026 – Axsome Therapeutics was upgraded by Morgan Stanley from “reduce” to “overweight”.
• 6/4/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright.

Insider Activity

In other news, Director Susan Mahony sold 300 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total transaction of $71,163.00. Following the completion of the transaction, the director owned 1,129 shares of the company’s stock, valued at approximately $267,810.09. The trade was a 20.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roger Jeffs sold 286 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $246.18, for a total value of $70,407.48. Following the transaction, the director directly owned 58,653 shares of the company’s stock, valued at approximately $14,439,195.54. The trade was a 0.49% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 155,852 shares of company stock valued at $37,230,112. Company insiders own 20.60% of the company’s stock.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.